Project description
Revolutionising skin cancer diagnostics
French company DAMAE Medical is developing new dermatological diagnostics based on a disruptive line-field confocal optical coherence tomography technology in a hand-held imaging device. The device captures in situ images of the skin layers with cellular resolution. It provides accurate diagnosis, thus minimising biopsies of benign lesions and improving detection of melanoma and non-melanoma skin cancers. Simultaneously, DAMAE is developing software to assist dermatologists with image interpretation and for telepathology and patient services. The company has completed the feasibility phase, resulting in a prototype of the technology and a consolidated atlas of skin cancer clinical images. The main objective of current phase 2 of the EU-funded OCTAV project is to achieve market assessment, clinical validation and regulatory approval.
Fields of science
Programme(s)
Funding Scheme
SME-2 - SME instrument phase 2
Coordinator
91400 Orsay
France
See on map